Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Gastric Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Gastroesophageal Junction Adenocarcinoma (183
)
Gastroesophageal Cancer (41
)
Gastric Adenocarcinoma (40
)
Gastroesophageal Junction Adenocarcinoma (183
)
Gastroesophageal Cancer (41
)
Gastric Adenocarcinoma (40
)
›
Associations
(777)
News
Trials
Search handles
@AGangiMD
@AJacomeMD
@AndresC27622123
@ArndtVogel
@BallenDF
@BatistaTP
@BenWestphalen
@BernhardDolesc1
@BiachiTiago
@BijoyTelivala
@CathyEngMD
@CharuAggarwalMD
@ChristianRolfo
@DanZhaoMD
@DenboJw
@DocCatenacci
@DrBonillaOnc
@DrChoueiri
@DrCrystalD
@DrEzraCohen
@DrMhidalgo
@DrMirallas
@DrR_DUNNE
@DrShubhamPant
@DrSteveMartin
@Dr_Ivanoncologo
@Dr_JJ_Berenguer
@Dr_R_Kurzrock
@DucreuxMichel
@ErikaHamilton9
@FAndreMD
@FilipHerpe
@FilippoPietran4
@FlavioRochaMD
@FogacciJoao
@GIcancerDoc
@GillSharlene
@HH_Oncodr
@HKennecke
@HalletJulie
@HassanSheikh_MD
@HosseinTaghiz11
@ILSONDavid
@JDekervel
@JeremyLDavisMD
@JoeChaoMD
@KellyBorgesAra2
@KlempnerSam
@KoheiShitara
@LAbushahin
@LFerri123
@LizzySmyth1
@MLPOncoData
@MPishvaian
@MadisonConces
@MansfieldPaul
@MichalisLiontos
@MoniquMeneses
@MyriamChalabi
@NDeVitoMD
@NataliyaUboha
@NicoleKuderer
@OsamaRahma2
@PTarantinoMD
@PamelaKunzMD
@PestanaRC
@RHuneburg
@Rndubois
@RussellPetty19
@RuthHe12
@RyanMoyMDPhD
@SKamath_MD
@SalemGIOncDoc
@SamWangMD
@Sarbaji85064063
@ShaalanBeg
@SirohiBhawna
@StephenVLiu
@SuyogCancer
@SyedAAhmad5
@Thalcin
@TimothyJBrownMD
@UmutDisel
@VivekSubbiah
@YJanjigianMD
@aLwOmbaT
@aftimosp
@anita_turk
@antonyruggeri
@badrinabeel
@benweinbergmd
@bpellegrino89
@cancerassassin1
@carlosbon78
@cczielinski
@clacardone
@doctorC369
@dr_yakupergun
@dralanburguete
@drallysonocean
@drjasonstarr
@drkpavithran
@drymtn
@duiliorocha_onc
@gabe_a_brooks
@guildsman
@hemoncwarner
@jesusanampa
@jgong15
@jrgralow
@jsoriamd
@khkbao
@kimtruss
@loconte
@marklewismd
@maryam_lustberg
@montypal
@mtmdphd
@pashtoonkasi
@rcarvalhoonco
@realbowtiedoc
@sundar__raghav
@tehfem
@tfleitask
@the_danielahn
@tmprowell
@tpjmd
@weldeiry
@weoncologists
Search handles
@AGangiMD
@AJacomeMD
@AndresC27622123
@ArndtVogel
@BallenDF
@BatistaTP
@BenWestphalen
@BernhardDolesc1
@BiachiTiago
@BijoyTelivala
@CathyEngMD
@CharuAggarwalMD
@ChristianRolfo
@DanZhaoMD
@DenboJw
@DocCatenacci
@DrBonillaOnc
@DrChoueiri
@DrCrystalD
@DrEzraCohen
@DrMhidalgo
@DrMirallas
@DrR_DUNNE
@DrShubhamPant
@DrSteveMartin
@Dr_Ivanoncologo
@Dr_JJ_Berenguer
@Dr_R_Kurzrock
@DucreuxMichel
@ErikaHamilton9
@FAndreMD
@FilipHerpe
@FilippoPietran4
@FlavioRochaMD
@FogacciJoao
@GIcancerDoc
@GillSharlene
@HH_Oncodr
@HKennecke
@HalletJulie
@HassanSheikh_MD
@HosseinTaghiz11
@ILSONDavid
@JDekervel
@JeremyLDavisMD
@JoeChaoMD
@KellyBorgesAra2
@KlempnerSam
@KoheiShitara
@LAbushahin
@LFerri123
@LizzySmyth1
@MLPOncoData
@MPishvaian
@MadisonConces
@MansfieldPaul
@MichalisLiontos
@MoniquMeneses
@MyriamChalabi
@NDeVitoMD
@NataliyaUboha
@NicoleKuderer
@OsamaRahma2
@PTarantinoMD
@PamelaKunzMD
@PestanaRC
@RHuneburg
@Rndubois
@RussellPetty19
@RuthHe12
@RyanMoyMDPhD
@SKamath_MD
@SalemGIOncDoc
@SamWangMD
@Sarbaji85064063
@ShaalanBeg
@SirohiBhawna
@StephenVLiu
@SuyogCancer
@SyedAAhmad5
@Thalcin
@TimothyJBrownMD
@UmutDisel
@VivekSubbiah
@YJanjigianMD
@aLwOmbaT
@aftimosp
@anita_turk
@antonyruggeri
@badrinabeel
@benweinbergmd
@bpellegrino89
@cancerassassin1
@carlosbon78
@cczielinski
@clacardone
@doctorC369
@dr_yakupergun
@dralanburguete
@drallysonocean
@drjasonstarr
@drkpavithran
@drymtn
@duiliorocha_onc
@gabe_a_brooks
@guildsman
@hemoncwarner
@jesusanampa
@jgong15
@jrgralow
@jsoriamd
@khkbao
@kimtruss
@loconte
@marklewismd
@maryam_lustberg
@montypal
@mtmdphd
@pashtoonkasi
@rcarvalhoonco
@realbowtiedoc
@sundar__raghav
@tehfem
@tfleitask
@the_danielahn
@tmprowell
@tpjmd
@weldeiry
@weoncologists
Filter by
Latest
9ms
The GLOW study is published! Kudos to the GI Oncology community and our patients. Zolbetuximab should be considered a standard option for CLDN18.2 positive gastroesophageal adenocarcinoma! @drallysonocean @pashtoonkasi @nyphospital @WCM_MeyerCancer https://t.co/G0wWPLz2Zr (@mdmanishshah)
9 months ago
Clinical
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
Vyloy (zolbetuximab)
9ms
In the phase 3 GLOW trial, CAPOX plus zolbetuximab significantly improved progression free survival and overall survival in patients with CLDN18.2+, HER2- untreated #GastricCancer or gastroesophageal junction adenocarcinoma @AstellasUS @mdmanishshah https://t.co/YYbLHhiyOq (@NatureMedicine)
9 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative
|
Vyloy (zolbetuximab)
9ms
Congratulations @mdmanishshah & team on these GLOWing 💡💡🌟🌟 results & for so brightly changing the standard treatment for patients with #claudin18point2 #gastroesophageal #cancer ! #MedEd #MedX #MedTwitter (@drallysonocean)
9 months ago
Clinical
|
CLDN18 (Claudin 18)
9ms
What gets paid for!? I remember having a HER2 3+ gastric cancer guy about 12 years ago. Got all better on Herceptin, but after 20 months there was progression. Couldn't get a second line therapy paid for. How do you do it? (Couldn't get free drug either). (@davideyoungmd)
9 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab)
9ms
“Evolving Landscape of Targeted Treatment Options for HER2-Positive Gastric/Gastroesophageal Adenocarcinomas” by Raisa Epistola, MD, Joseph Chao, MD, and Jennifer Lee, MD https://t.co/lPI7BsMr8o @JoeChaoMD @HarborUCLA @cityofhope (@clinadvances)
9 months ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
9ms
Huge congrats to @JohnDKaralisMD and @SamWangMD . Gastric cancer dream team with another impressive project 👏🏾👏🏾 (@GilbertZMurimwa)
9 months ago
9ms
Our review on targeted/IO strategies in HER2+ve gastric/GEJ adenocarcinomas is out now in @JIPOEditors. As always, it has been a delight working with Dr. @AnwaarSaeed3! https://t.co/sUida2A4lt (@HMAbushukair)
9 months ago
Review
|
HER-2 (Human epidermal growth factor receptor 2)
9ms
This @TumoirJ research explores #prognostic and #predictive role ➡️TK-1, TP, Ang-2, and Tie-2 mRNA expression🧬 in plasma-derived microvesicles 🩸 ➡️Chemo-refractory metastatic #ColorectalCancer patients 🔗https://t.co/7wboBZsMZ4 @LorenzaRimassa #gicancers #gastriccancer (@TumoriJ)
9 months ago
Clinical • Metastases
9ms
EMA Accepts Marketing Application for Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma @EMA_News #esocsm #oncology https://t.co/n9TlF3s5cv (@OncLive)
9 months ago
CLDN18 (Claudin 18)
|
Vyloy (zolbetuximab)
9ms
Interested in the latest in #CARTcelltherapy and treatment of HER2+ #esophagogastriccancer and KRAS-G12 C-mutant #NSCLC? You'll find brief summaries of work by @MSKCancerCenter's @jaeparkmd, @YJanjigianMD, @SteveMaronMD, @rohit_thum, + @KCArbourMD here. https://t.co/GDzcsZ7csG (@MSK_DeptOfMed)
9 months ago
CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
10ms
#ClinicalTrial EA2183, led by @NataliyaUboha of @UWHealth, is testing the addition of #radiotherapy to chemotherapy for patients w/ #esophageal and #GastricCancer. For more: https://t.co/YDD5pHUqPv #StomachCancer #GICSM #esocsm (@eaonc)
10 months ago
Clinical
10ms
Signet-Ring / Poorly Cohesive adenocarcinoma of pancreas, No CDH1 mutations in this highly aggressive pancreatic cancer variant (unlike gastric signet ring cell cancers). Great images. (@RZitwer)
10 months ago
CDH1 (Cadherin 1)
|
CDH1 mutation
10ms
Great morning discussing novel biomarkers in gastric cancer in 🇧🇷 @rcarvalhoonco @AJacomeMD @FogacciJoao @RachelRiechelm2 (@PestanaRC)
10 months ago
10ms
TODAY!! ENDOLUMINAL SURGERY FOR GI NEOPLASIA. Join @ScottRSteeleMD @jsommov @EmreGorgunMD @amitbhattMD @JohnVargoMD @OlgaLavryk @CleClinicMD CME event. Endo resection esophageal/gastric neoplasia/early CR neoplasia. Stenting GI malignancies. https://t.co/r8Uo5HXNdi (@RitaRys1)
10 months ago
CME • Surgery
10ms
EGFR Inhibition in EGFR–Amplified Gastroesophageal Cancer 60 pts ORR All pts➡️43% ChT plus EGFRi➡️57% mPFS All pts➡️4.6 mo ChT plus EGFRi➡️6.0 mo First line➡️6.9 mo 📌Well-selected patients with EGFR-amplified GEA derive significant benefit from EGFRi @JCO_ASCO… https://t.co/CJfrsAqzMH (@dr_yakupergun)
10 months ago
Clinical
|
EGFR amplification
10ms
Check out this on demand webinar on gastroesophageal cancer provided by experts @YJanjigianMD @KlempnerSam and @LizzySmyth1 Now available as an accredited e-learning https://t.co/srAajgJZtN #MedEd (@giconnectInfo)
10 months ago
10ms
Raghav @sundar__raghav s talk in Singapore Gastric cancer NUS JSPS Meeting @somusp9 https://t.co/4plT5fRAX2 (@sundar_s1955)
10 months ago
10ms
Raghav @sundar__raghav s talk in Singapore Gastric cancer NUS JSPS Meeting @somusp9 https://t.co/4plT5fRAX2 (@sundar_s1955)
10 months ago
10ms
👉Interesting strategy to consider in future randomized trials for locally advanced gastric cancer patients: 📢total neoadjuvant therapy could be a feasible option instead of perioperative chemotherapy? @ACTEG2023 @oncolvisa @cpericay @TamaraSN2 @DrNotarioR (@chierrocarbo)
10 months ago
Clinical • Metastases
10ms
Hey! All those cancers have a common target - the Genetic Aspect! Research indicates the B-Raf gene is frequently mutated in colorectal, non-small cell lung, and gastric cancer. In breast cancer,estrogen receptors are the key target. Hope it helps! #oncologyboards #cancerresearch (@NandanDuddukuri)
10 months ago
BRAF (B-raf proto-oncogene) • ER (Estrogen receptor)
10ms
Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression @Aiims1742 @IamLinghua #Cancers #MedEd #MedTwitter #gastric #immune https://t.co/uAK43WcBAn (@imedverse)
10 months ago
Stroma
10ms
🎥@FilippoPietran4 of @IstTumori discusses testing methods for microsatellite instability in gastric & GEJ cancers at #WCGIC23. Immunohistochemistry & NGS are viable options, with NGS being more cost-effective: ➡️https://t.co/lJGhPKpaF5⬅️ @myESMO (@VJOncology)
10 months ago
HEOR • Next-generation sequencing • Cost effectiveness
|
MSI (Microsatellite instability)
10ms
From our super 🌟 @IamLinghua & colleagues @MDAndersonNews in @Cancer_Cell Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression https://t.co/KN5qJM9RpC The largest single cell RNAseq dataset in #GastricCancer https://t.co/i4H8hQLeUF (@Aiims1742)
10 months ago
Stroma
10ms
#Tcells T cells #leukemia #leukaemia #cancer #autoimmune #autoimmunity #immunotherapy #bladdercancer stomach cancer #braincancer #breastcancer #midwifery #childhoodcancer uterine cancer #coloncancer #kidneycancer #livercancer #lymphoma #myeloma pancreatic cancer #ovariancancer (@SilkeLeFay)
10 months ago
Clinical
10ms
Out in @CCR_AACR. @SteveMaronMD @ILSONDavid @JeeyunM @YJanjigianMD and others. Determinants of survival in HER2+ metastatic esophagogastric cancer https://t.co/1JnQbb0krS (@KlempnerSam)
10 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
10ms
New #JITC article: Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial https://t.co/0MlgE4Cb9b @KoheiShitara (@jitcancer)
10 months ago
Clinical • Clinical data • Metastases
|
Keytruda (pembrolizumab) • paclitaxel
10ms
Trastuzumab deruxtecan in HER2+ GC or GEJ cancer with progression on or after a trastuzumab in the USA & Europe @TheLancetOncol https://t.co/kJEgnmzYdn 🔎DESTINY-02, 79 pts 👉ORR 42%, DoR 8.1, mPFS 5.6, mOS 12.1 mo 👉Clinical activity, DESTINY-Gastric04 waited @myESMO @OncoAlert https://t.co/hLm9rlUdoF (@ArndtVogel)
10 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
10ms
3% mortality in a very difficult to treat disease like gastric cancer is pretty bad... Most patients do not even survive to this line of therapy. ECOG1 needed! (@BremenStudio)
10 months ago
Clinical
10ms
@WCGIC In a brief, only 25 years in gastric cancer!! 😊👏 @AndresC27622123 brillant! (@Juanmaoconnor)
10 months ago
10ms
Program on Day 1 - focused on cervical and lung cancers Program on Day 2 - will focus on breast, H&N and gastric cancers followed by evidence based cost effective immuno/targeted therapies for common cancers @Umeshshetty72 @cspramesh (@ravimteza)
10 months ago
HEOR • Cost effectiveness
10ms
Great to be back in Barcelona at #WCGIC2023 sharing some #gastriccancer #microbiome work (@DrMaryBooth)
10 months ago
10ms
Epidemiology of Gastric Intestinal Metaplasia and Gastric Cancer 📕 Read here: https://t.co/uM6T4571uX @CodeyPham @TheresaNguyenMD @SeragHashem @BCMDeptMedicine @bcm_gihep @BCM_InternalMed #gastriccancer #gastricintestinalmetaplasia #GITwitter #MedTwitter #SurgTwitter (@foregut_journal)
10 months ago
Clinical
10ms
#ClinicalTrial EA2183, led by @NataliyaUboha of @UWHealth, is testing the addition of #radiotherapy to chemotherapy for patients w/ #esophageal and #GastricCancer. For more: https://t.co/YDD5pHTSZX #StomachCancer #GICSM #esocsm (@eaonc)
10 months ago
Clinical
10ms
Tune in July 12 ENDOLUMINAL SURGERY FOR GI NEOPLASIA. Join @ScottRSteeleMD @jsommov @EmreGorgunMD @amitbhattMD @JohnVargoMD @OlgaLavryk @CleClinicMD CME event. Endo resection esophageal/gastric neoplasia/early CR neoplasia. Stenting GI malignancies. https://t.co/r8Uo5HXNdi (@RitaRys1)
10 months ago
CME • Surgery
10ms
📣 Dr. John L. Marhsall (@marshalj23) explains how to incorporate into practice the latest data on #HER2-positive gastric/gastroesophageal junction #cancers ✅ Updating healthcare professionals' know-how in the use of data is key for the benefit of #patients (@FundacionECO)
10 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
10ms
#WCGIC2023 💊 Emerging 🎯 in #GI cancer 🪑Dr. Van Cutsem + Dr. Carnero 🗣️@ValeGambardella 🎯 HER2 ✔️ T-DxT for #GastricCancer #DestinyGastric01 2nd line #FDA --> ⏳#DestinyGastric02 ✔️Trastuzumab + tucatinib for #CCR #MOUNTAINEER ✔️Zanidatamab #BiliaryTract #HERIZONBTC01 @WCGIC (@DrMirallas)
10 months ago
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab) • Tukysa (tucatinib) • zanidatamab (ZW25)
10ms
Liquid biopsy guided anti-HER2 therapy presented today at #WGIC23. Appreciate the support from Guardant. @gcleslieb @Amitmahipal79 @UHhospitals @GastricCancerFD (@doctorC369)
10 months ago
Clinical • Liquid biopsy • Biopsy
10ms
Outstanding gastroesophageal cancer session at #WCGIC2023 and excellent abstract presentations from colleagues of our group 👏🏻@FilippoPietran4 @LizzySmyth1 @KoheiShitara #giovannirandon @Mom_enji (@margheambro1)
10 months ago
10ms
pCR in gastric cancer does not seem to be surrogate for survival. (@dr_yakupergun)
10 months ago
10ms
@LizzySmyth1 Wonderful review about ICI in advanced gastric cancer. Two key points to next double mab clinical trials: 1. We do not want excess AE toxicity (ICI + Claudins or FGFR2b ab) 2. We need a refundable (as worldwide as possible) treatment. #WCGIC2023 (@BallenDF)
10 months ago
Clinical • Review • Metastases
10ms
Remarkable keynote on molecular classification of #GastricCancer- the field will evolve to classify the TME AND tumour epithelium, not forgetting epigenetics! @myESMO #WCGIC2023 (@graokane)
10 months ago
10ms
Fantastic talk by @FilippoPietran4 on MSI-H/dMMR esophagogastric cancers. I encourage everybody to rewatch! #WCGIC2023 @myESMO (@MyriamChalabi)
10 months ago
MSI (Microsatellite instability)
|
MSI-H/dMMR
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login